Biohaven Pharma (BHVN) Misses Q2 EPS by 172c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• JPMorgan Upgrades Graphic Packaging Holding Company (GPK) to Overweight
• Berenberg Reiterates Buy Rating on AXA SA (CS:FP) (AXAHY)
• M&C Saatchi PLC (SAA:LN) PT Lowered to GBP1.62 at Deutsche Bank